stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) Return on invested capital
NeoGenomics, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −2.97%, up 4.1 percentage points from fiscal 2025 (−7.11%). Over the past ten years it has ranged from −8.94% (fiscal 2022) to 1.87% (fiscal 2019); the current reading is higher than 18% of that period. That is below the Diagnostics & Research industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −7.11% | (1.66) |
| FY2024 | −5.45% | 0.88 |
| FY2023 | −6.33% | 2.61 |
| FY2022 | −8.94% | (2.39) |
| FY2021 | −6.55% | (5.03) |
| FY2020 | −1.52% | (3.39) |
| FY2019 | 1.87% | 0.36 |
| FY2018 | 1.51% | 0.81 |
| FY2017 | 0.70% | 0.17 |
| FY2016 | 0.53% | 1.92 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| CDNA CareDx, Inc. compare | 33.6% |
| VCYT Veracyte, Inc. compare | 4.33% |
| ADPT Adaptive Biotechnologies Corporation compare | 0.00% |
| FRNM Freenome, Inc compare | 0.00% |
| NEO NeoGenomics, Inc. | −2.97% |
| CSTL Castle Biosciences, Inc. compare | −3.63% |
| OPK OPKO Health, Inc. compare | −6.72% |
| WGS GeneDx Holdings Corp. compare | −27.7% |
| PSNL Personalis, Inc. compare | −358.4% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on NEO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement